Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

BACKGROUND: The inclusion of immune checkpoint inhibitors (ICIs) in the treatment of operable stage III non-small-cell lung cancer is becoming a new standard. Programmed death-ligand 1 (PD-L1) protein expression on tumor cells has emerged as the most important biomarker for sensitivity to ICIs targe...

Descripción completa

Detalles Bibliográficos
Autores principales: König, D., Savic Prince, S., Hayoz, S., Zens, P., Berezowska, S., Jochum, W., Stauffer, E., Braunersreuther, V., Trachsel, B., Thierstein, S., Mark, M., Schmid, S., Curioni-Fontecedro, A., Addeo, A., Opitz, I., Guckenberger, M., Früh, M., Betticher, D.C., Ris, H.-B., Stupp, R., Rothschild, S.I., Bubendorf, L., Pless, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515281/
https://www.ncbi.nlm.nih.gov/pubmed/37441877
http://dx.doi.org/10.1016/j.esmoop.2023.101595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515281/
https://www.ncbi.nlm.nih.gov/pubmed/37441877
http://dx.doi.org/10.1016/j.esmoop.2023.101595

Ejemplares similares